|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SIGLEC15 |
Gene summary for SIGLEC15 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SIGLEC15 | Gene ID | 284266 |
| Gene name | sialic acid binding Ig like lectin 15 | |
| Gene Alias | CD33L3 | |
| Cytomap | 18q12.3 | |
| Gene Type | protein-coding | GO ID | GO:0001501 | UniProtAcc | Q6ZMC9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 284266 | SIGLEC15 | PTC01 | Human | Thyroid | PTC | 1.09e-02 | 1.01e-01 | 0.1899 |
| 284266 | SIGLEC15 | PTC04 | Human | Thyroid | PTC | 2.29e-02 | 7.47e-02 | 0.1927 |
| 284266 | SIGLEC15 | PTC06 | Human | Thyroid | PTC | 1.69e-04 | 1.53e-01 | 0.2057 |
| 284266 | SIGLEC15 | PTC07 | Human | Thyroid | PTC | 2.74e-06 | 1.85e-01 | 0.2044 |
| 284266 | SIGLEC15 | ATC09 | Human | Thyroid | ATC | 8.38e-13 | 5.59e-01 | 0.2871 |
| 284266 | SIGLEC15 | ATC12 | Human | Thyroid | ATC | 2.61e-10 | 3.18e-01 | 0.34 |
| 284266 | SIGLEC15 | ATC1 | Human | Thyroid | ATC | 1.33e-13 | 6.39e-01 | 0.2878 |
| 284266 | SIGLEC15 | ATC4 | Human | Thyroid | ATC | 3.02e-16 | 4.30e-01 | 0.34 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0032956113 | Thyroid | PTC | regulation of actin cytoskeleton organization | 182/5968 | 358/18723 | 4.64e-14 | 2.79e-12 | 182 |
| GO:0032970113 | Thyroid | PTC | regulation of actin filament-based process | 197/5968 | 397/18723 | 8.91e-14 | 4.89e-12 | 197 |
| GO:0030099113 | Thyroid | PTC | myeloid cell differentiation | 160/5968 | 381/18723 | 1.75e-05 | 1.82e-04 | 160 |
| GO:00603486 | Thyroid | PTC | bone development | 90/5968 | 205/18723 | 1.89e-04 | 1.42e-03 | 90 |
| GO:0032970210 | Thyroid | ATC | regulation of actin filament-based process | 208/6293 | 397/18723 | 5.82e-15 | 3.80e-13 | 208 |
| GO:0032956210 | Thyroid | ATC | regulation of actin cytoskeleton organization | 190/6293 | 358/18723 | 1.73e-14 | 1.01e-12 | 190 |
| GO:006034813 | Thyroid | ATC | bone development | 102/6293 | 205/18723 | 1.18e-06 | 1.52e-05 | 102 |
| GO:003009933 | Thyroid | ATC | myeloid cell differentiation | 170/6293 | 381/18723 | 4.26e-06 | 4.68e-05 | 170 |
| GO:00487715 | Thyroid | ATC | tissue remodeling | 78/6293 | 175/18723 | 1.60e-03 | 8.04e-03 | 78 |
| GO:0002573110 | Thyroid | ATC | myeloid leukocyte differentiation | 86/6293 | 208/18723 | 1.15e-02 | 4.11e-02 | 86 |
| GO:00468491 | Thyroid | ATC | bone remodeling | 41/6293 | 90/18723 | 1.21e-02 | 4.30e-02 | 41 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SIGLEC15 | SNV | Missense_Mutation | c.939N>T | p.Leu313Phe | p.L313F | Q6ZMC9 | protein_coding | tolerated_low_confidence(0.07) | probably_damaging(0.996) | TCGA-BH-A0EI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| SIGLEC15 | SNV | Missense_Mutation | c.40N>A | p.Val14Ile | p.V14I | Q6ZMC9 | protein_coding | tolerated_low_confidence(0.7) | benign(0) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| SIGLEC15 | SNV | Missense_Mutation | novel | c.701N>A | p.Arg234His | p.R234H | Q6ZMC9 | protein_coding | deleterious(0.05) | probably_damaging(0.945) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SIGLEC15 | SNV | Missense_Mutation | novel | c.933A>C | p.Glu311Asp | p.E311D | Q6ZMC9 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.967) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SIGLEC15 | SNV | Missense_Mutation | rs775151990 | c.956G>A | p.Arg319Gln | p.R319Q | Q6ZMC9 | protein_coding | tolerated_low_confidence(0.55) | benign(0.001) | TCGA-AJ-A3OK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | CR |
| SIGLEC15 | SNV | Missense_Mutation | novel | c.918N>T | p.Gln306His | p.Q306H | Q6ZMC9 | protein_coding | tolerated(0.09) | benign(0.007) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SIGLEC15 | SNV | Missense_Mutation | rs764771452 | c.955N>T | p.Arg319Trp | p.R319W | Q6ZMC9 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.451) | TCGA-B5-A0JZ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | PD |
| SIGLEC15 | SNV | Missense_Mutation | novel | c.44N>C | p.Leu15Pro | p.L15P | Q6ZMC9 | protein_coding | deleterious_low_confidence(0) | benign(0.261) | TCGA-DF-A2KN-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
| SIGLEC15 | SNV | Missense_Mutation | novel | c.87N>T | p.Glu29Asp | p.E29D | Q6ZMC9 | protein_coding | tolerated_low_confidence(0.22) | benign(0.023) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
| SIGLEC15 | SNV | Missense_Mutation | rs775151990 | c.956G>A | p.Arg319Gln | p.R319Q | Q6ZMC9 | protein_coding | tolerated_low_confidence(0.55) | benign(0.001) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |